The expanding CML treatment landscape: an introspective commentary.
作者信息
Lipton Jeffrey H
机构信息
Leukemia Group, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.
出版信息
Blood Cancer J. 2023 Sep 13;13(1):145. doi: 10.1038/s41408-023-00918-3.
Abstract
摘要
相似文献
1
The expanding CML treatment landscape: an introspective commentary.
Blood Cancer J. 2023 Sep 13;13(1):145. doi: 10.1038/s41408-023-00918-3.
2
Meditation experience predicts introspective accuracy.
PLoS One. 2012;7(9):e45370. doi: 10.1371/journal.pone.0045370. Epub 2012 Sep 25.
3
Three types of consciousness.
Ciba Found Symp. 1979(69):235-53. doi: 10.1002/9780470720523.ch13.
4
Introspective Meditation before Seeking Pleasurable Activities as a Stress Reduction Tool among College Students: A Multi-Theory Model-Based Pilot Study.
Healthcare (Basel). 2022 Mar 25;10(4):614. doi: 10.3390/healthcare10040614.
5
The surprising role of stimulus modality in the dual-task introspective blind spot: a memory account.
Psychol Res. 2022 Jun;86(4):1332-1354. doi: 10.1007/s00426-021-01545-y. Epub 2021 Jul 13.
6
The electrophysiology of introspection.
Conscious Cogn. 2006 Dec;15(4):662-72. doi: 10.1016/j.concog.2006.05.002. Epub 2006 Aug 23.
7
Care and culture: an introspective commentary.
West J Nurs Res. 2001 Dec;23(8):812-7; discussion 836-8. doi: 10.1177/01939450122045645.
8
Biological Stress Reactivity and Introspective Sensitivity: An Exploratory Study.
Front Psychol. 2020 Mar 26;11:543. doi: 10.3389/fpsyg.2020.00543. eCollection 2020.
9
Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia.
Leuk Lymphoma. 2021 Sep;62(9):2064-2078. doi: 10.1080/10428194.2021.1894652. Epub 2021 May 4.
10
Are introspective reaction times affected by the method of time estimation? A comparison of visual analogue scales and reproduction.
Atten Percept Psychophys. 2015 Apr;77(3):978-84. doi: 10.3758/s13414-014-0804-2.
本文引用的文献
1
Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights.
Cells. 2023 Jun 23;12(13):1703. doi: 10.3390/cells12131703.
2
Targeted Therapy and Personalized Medicine.
Cancer Treat Res. 2023;185:177-205. doi: 10.1007/978-3-031-27156-4_10.
3
Treatment after failure of frontline therapy of chronic myeloid leukemia in chronic phase including allogeneic hematopoietic stem cell transplantation.
Blood Res. 2023 Apr 30;58(S1):109-113. doi: 10.5045/br.2023.2023054.
4
Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: From clinical trials to real-life settings.
Front Oncol. 2023 Apr 5;13:1146108. doi: 10.3389/fonc.2023.1146108. eCollection 2023.
5
Management of chronic myeloid leukemia in 2023 - common ground and common sense.
Blood Cancer J. 2023 Apr 24;13(1):58. doi: 10.1038/s41408-023-00823-9.
6
Chronic Myeloid Leukemia, from Pathophysiology to Treatment-Free Remission: A Narrative Literature Review.
J Blood Med. 2023 Apr 6;14:261-277. doi: 10.2147/JBM.S382090. eCollection 2023.
7
Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia.
Blood Res. 2023 Apr 30;58(S1):S58-S65. doi: 10.5045/br.2023.2023035. Epub 2023 Apr 7.
8
The Bone Marrow Immune Microenvironment in CML: Treatment Responses, Treatment-Free Remission, and Therapeutic Vulnerabilities.
Curr Hematol Malig Rep. 2023 Apr;18(2):19-32. doi: 10.1007/s11899-023-00688-6. Epub 2023 Feb 13.
9
Management of TKI-resistant chronic phase CML.
Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):129-137. doi: 10.1182/hematology.2022000328.
10
Mechanisms of Resistance and Implications for Treatment Strategies in Chronic Myeloid Leukaemia.
Cancers (Basel). 2022 Jul 6;14(14):3300. doi: 10.3390/cancers14143300.
Zotero 插件